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Objectives: To determine the mechanism of high-level resistance to fluoroquinolone antimicrobials
in toxin-A-negative, toxin-B-positive (A–B+) Clostridium difficile isolates.
Methods: Following culture 16–23S PCR ribotyping was used to determine genomic relationships
between A–B+ C. difficile isolates. Antimicrobial susceptibilities were determined using Etests in the
presence and absence of the efflux pump inhibitors reserpine (20 mg/mL), L-phenylalanine-L-arginine-b-
naphthylamide (PAbN; 20 mg/mL) and verapamil (100 mg/mL). Genomic regions including the quinolone-
resistance-determining-region (QRDR) of gyrA and gyrB were amplified and characterized.
Results: PCR ribotyping profiles identified one major cluster of A–B+ C. difficile, universally resistant
to the fluoroquinolones tested (ofloxacin, ciprofloxacin, levofloxacin, moxifloxacin and gatifloxacin;
MICs > 32 mg/L). All isolates with high-level resistance had a transversion mutation (A!T) resulting in
the amino acid substitution Asp-426!Val in gyrB. Non-clonal isolates were susceptible to moxifloxacin
and gatifloxacin (MICs 0.3 and 0.4 mg/L, respectively) with reduced susceptibility to levofloxacin (MIC 3
mg/L) consistent with the wild-type genotype. The MICs for resistant isolates were not significantly
affected by the addition of any of the efflux pump inhibitors. No amino acid substitutions were identified
in the QRDR of gyrA.
Conclusions: High-level resistance to fluoroquinolones in A–B+ C. difficile is associated with a novel
transversion mutation in gyrB. The emergence of universal resistance in different C. difficile strain types
may be a factor promoting outbreaks in hospitals.
Keywords: fluoroquinolone resistance, A–B+ C. difficile, transversion mutation
Introduction
Clostridium difficile is a major cause of bacterial diarrhoea in
the developed world.1 Patients in hospital receiving antibiotics
are the most at risk. Certain classes of antimicrobials have been
associated with a high risk of C. difficile-associated disease
(CDAD) including clindamycin, cephalosporins and ampicillin/
amoxicillin.1 Historically, fluoroquinolone antimicrobials were
considered low risk for CDAD, although a number of case reports
associated with ciprofloxacin exposure have been published.2
However, recent studies indicate a shift in the risk associated with
the use of fluoroquinolone antimicrobials.3–5
The risk of antibiotic-associated CDAD appears to increase if
C. difficile is resistant to the administered antibiotic. A number of
outbreaks in different states in the United States were associated
with a clonal clindamycin-resistant strain, wherein this drug
was identified as a specific risk factor.6 More recently, an
investigation into an outbreak caused by the hyper-virulent
fluoroquinolone-resistant strain (PCR-027/NAP1) in the Quebec
region of Canada indicated that fluoroquinolone antimicrobials
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were more likely to induce CDAD.4 Furthermore, Muto et al.5
reported that exposure to levofloxacin was an independent risk
factor for CDAD in a large outbreak in Pittsburgh.
A recent outbreak at one Dublin hospital identified the
emergence of a clonal toxin-A-negative, toxin-B-positive
(A–B+) C. difficile strain type demonstrating high-level resistance
to several fluoroquinolone antibiotics. A second investigation
identified these strains in a number of additional healthcare
settings in Dublin. The purpose of this study was to determine the
contribution of target gene mutations and active efflux to
fluoroquinolone resistance in these isolates.
Materials and methods
Bacterial strains and culture
Seventy C. difficile strains were studied. These included 30 repre-
sentative C. difficile strains that were collected during surveillance of
a hospital outbreak in 2003, 10 isolates collected from that institution
prior to the outbreak and 30 isolates collected from six healthcare
settings in Dublin in 2004. C. difficile strains were cultured on
cycloserine-cefoxitin-fructose agar (CCFA). Type strains VPI10463
and 1470 along with a non-toxigenic strain (R10567) were included
as controls.
Antibiotic susceptibility of C. difficile
Fluoroquinolone susceptibility was determined using Etests (AB
Biodisk, Solna, Sweden). The MIC was interpreted by the Clinical
and Laboratory Standards Institute (CLSI) breakpoints for trovo-
floxacin (2 mg/L, susceptible; 4 mg/L, intermediate; 8 mg/L,
resistant).
Molecular analysis of C. difficile strains
Genomic DNA was extracted from broth cultures of C. difficile and
PCR ribotyping and PCR–RFLP (toxinotyping) were performed as
previously described.
PCR amplification and sequencing of the quinolone-
resistance-determining-region (QRDR) of gyrA and gyrB
Primers GyrAF (TTG AAA TAG CGG AAG AAA TGA), GyrAR
(TTG CAG CTG TAG GGA AAT C), GyrBF (GAA GGT CAA
ACT AAA ACA AA) and GyrBR (GGG CTC CAT CTA CAT CAG)
were designed from the sequence of the C. difficile 630
genome and were used to amplify 633 and 514 bp amplicons from
gyrA and gyrB, respectively (http://www.sanger.ac.uk/Projects/
C_difficile/blast_server.shtml). Amplicons were purified using
a QIAquick PCR purification kit (Qiagen, GmbH, Germany)
and sequenced commercially by Qiagen. Clustal W amino acid
sequence alignments were produced for comparison.
Nucleotide sequence accession numbers
The nucleotide sequence data for partial sequences of the gyrB
gene were submitted to GenBank and were assigned the accession
numbers DQ642011, DQ642012 and DQ642013, respectively.
Efflux contribution
Ten representative isolates (Table 1) were chosen for efflux
studies. The MICs of all five antibiotics were determined using
Etest strips, in the presence and absence of the following
efflux pump inhibitors: reserpine (20 mg/mL); L-phenylalanine-
L-arginine-b-naphthylamide (20 mg/mL); and verapamil
(100 mg/mL). Concentrations of PAbN and reserpine up to
80 mg/mL, and verapamil up to 800 mg/mL, were used to deter-
mine the effect (if any) of these inhibitors on bacterial growth.
Results
Antimicrobial susceptibility patterns and efflux
contribution
Sixty C. difficile were universally resistant to all five fluoro-
quinolones tested (MICs > 32 mg/L). Control isolates VPI10463,
1470 and R10567 and 10 clinical isolates were susceptible
Table 1. Characterization of representative isolates in this study
Fluoroquinolone MIC (mg/L)
Isolate Toxigenic status Ribotype ciprofloxacin ofloxacin levofloxacin gatifloxacin moxifloxacin Amino acid substitution in GyrB
M3a A–B+ A >32 >32 >32 >32 >32 Asp-426!Val
M7a A–B+ A >32 >32 >32 >32 >32 Asp-426!Val
J11a A–B+ A >32 >32 >32 >32 >32 Asp-426!Val
V21a A–B+ A >32 >32 >32 >32 >32 Asp-426!Val
V64a A–B+ A >32 >32 >32 >32 >32 Asp-426!Val
M47b A+B+ B >32 >32 3 0.38 0.25 Asp-426
M52c A+B+ C >32 >32 3 0.38 0.25 Asp-426
R10567d A–B– D >32 >32 3 0.38 0.25 Asp-426
1470d A–B+ A >32 >32 3 0.38 0.25 Asp-426
VPI10463d A+B– E >32 >32 3 0.38 0.25 Asp-426
aClinical isolates representing the 60 A–B+ C. difficile in this study.
bClinical isolate representing four of the ten A+B+ clinical isolates.
cClinical isolate representing six of the ten A+B+clinical isolates.
dControl isolates and type strains.
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to moxifloxacin and gatifloxacin (MICs of 0.3 and 0.4 mg/L,
respectively) and showed reduced susceptibility to levofloxacin
(MIC 3 mg/L). These strains were resistant to ciprofloxacin and
ofloxacin. The MICs for representative isolates are shown in
Table 1. The addition of efflux pump inhibitors had no effect on
MICs or on bacterial growth of any of the isolates investigated
(data not shown).
16–23S PCR ribotyping
16–23S ribotyping identified one major cluster containing
60 A–B+ isolates. Toxinotyping confirmed that these isolates
were toxinotype VIII (PCR-017) (data not shown). The remaining
ten clinical isolates belonged to two different ribotype groups
(data not shown).
Amplification and sequence analysis of gyrA and gyrB
Amplicons from gyrA and gyrB were sequenced for 10 repre-
sentative isolates (Table 1). Sequence analysis of the QRDR of
gyrA revealed a number of silent mutations. Deduced sequence
analysis of the QRDR of gyrB revealed an Asp-426!Val amino
acid substitution at codon 426 in all resistant isolates. A Ser-
366!Ala substitution was found in all A–B+ C. difficile (data not
shown). As this substitution was found in clinical strains resistant
to moxifloxacin, gatifloxacin and levofloxacin and in the 1470
type strain that was susceptible to moxifloxacin and gatifloxacin,
it is unlikely to contribute to the fluoroquinolone-resistant
phenotype. No amino acid substitutions were identified in
any of the susceptible A+B+ clinical isolates or control strains
R10567 and VPI10463.
Discussion
This study identified an A–B+ clone of C. difficile resistant to five
fluoroquinolone antimicrobials. The b-subunit of DNA gyrase is
the primary target wherein a single nucleotide transversion
resulted in a novel Asp!Val substitution at codon 426. This is
the first report of gyrB mutations in this strain type.
Fluoroquinolone resistance associated with chromosomal
mutations in gyrA and gyrB has been previously described in
C. difficile. Ackermann et al.7 described two substitutions in gyrA
corresponding to codon 83 in Escherichia coli. Thirteen of 18
isolates studied had a substitution corresponding to Thr-83!Ile
while one strain had a Thr-83!Val substitution. Dridi et al.8
described mutations in gyrA and gyrB associated with fluoro-
quinolone resistance in several serogroups of C. difficile. The
substitutions in gyrA included Thr-83!Ile in six strains
(serogroups H1, A9 and 1C), an Asp-71!Val substitution in
one strain (serogroup H) and an Ala-118!Thr substitution
in one serogroup D strain. Two substitutions in gyrB, including
an Arg-447!Leu substitution in a single non-typeable isolate
and an Asp-426!Asn substitution in five isolates (4 serogroup C
and 1 serogroup K), were described.
Codon Asp-426 has been highlighted as a critical region in
gyrB and mutations corresponding to this codon have been asso-
ciated with fluoroquinolone resistance in E. coli, Staphylococcus
aureus and Streptococcus pneumoniae.9 In C. difficile, Dridi
et al.8 described an Asp-426!Asn substitution in five isolates
with MICs of moxifloxacin of 8 or 16 mg/L. Substitution of Asp
with Asn results in the replacement of a negatively charged
polar hydrophilic amino acid with an uncharged polar residue.
In this study, Asp is substituted with valine at position 426 in
fluoroquinolone-resistant A–B+ C. difficile isolates. This results in
the introduction of a non-polar side chain and the loss of negative
charge. Moreover, as valine is a branched chain amino acid it can
add bulk to the protein backbone thereby restricting conforma-
tional flexibility. It is tempting to speculate that Val-426 may alter
the shape of the drug-binding pocket more significantly than
Asn thereby producing a more extreme phenotype, as measured
by MIC. This may explain the high-level resistance encountered
in the A–B+ C. difficile strains in this study.
Increased fluoroquinolone resistance associated with newer
groups of fluoroquinolones with increased anti-anaerobic activity
has been described.9 Ackerman et al.10,11 reported C. difficile
moxifloxacin resistance rates of 12% and 50% in two studies
where the majority of resistant isolates clustered into two clonal
groups. None of the patients with moxifloxacin-resistant
C. difficile strains had received this antibiotic. Similarly, in this
study neither moxifloxacin nor gatifloxacin was used clinically.
This highlights the possibility that resistance to the newer
antimicrobials may result from mechanisms that were acquired
or evolved following exposure to older fluoroquinolone
antimicrobials.
Isolates demonstrating high-level resistance to fluoroquino-
lones in this study were clonal. These A–B+ strains were isolated
from patients from three different university hospitals along with
three community-acquired specimens indicating the emergence
and dissemination of this strain type throughout the greater Dublin
area. Wilcox et al.12 have previously highlighted the importance
of typing isolates when describing rates of resistance. It is
possible that acquired antimicrobial resistance may be at least one
mechanism that contributed to the selection and proliferation of
this strain type in an environment where fluoroquinolones are
frequently used.
In conclusion, we report a novel transversion mutation in
gyrB associated with high-level fluoroquinolone resistance in
C. difficile PCR-017. Efflux pump activity does not appear to
contribute to the resistance phenotype. Emergence of resistance
to fluoroquinolones in C. difficile strains may be a factor that
contributes to the persistence and dissemination of strain types
in the hospital environment. Fluoroquinolone use is now a
recognized high risk of CDAD; therefore careful use of this
antibiotic class needs to be encouraged as part of infection control
policies to reduce C. difficile disease.
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